Search results for " immunology"

showing 10 items of 1841 documents

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocy…

2018

Relapse of acute leukemia (AL) after allogeneic hematopoietic cell transplantation (Allo-HCT) entails a dismal prognosis. In this scenario, donor lymphocyte infusions (DLIs) and second Allo-HCT are two major approaches. We compared outcomes of AL patients treated for relapse with DLI or second Allo-HCT after receiving debulking therapy. In total, 46 patients were included in the study; 30 (65%) had acute myeloid leukemia and 16 (35%) had acute lymphoblastic leukemia. The median age was 38 years (range 4-66). Twenty-seven patients received a second Allo-HCT and 19 patients received DLI. The median follow-up of the cohort was 273 days (range 9-7013). Overall survival (OS), disease-free surviv…

OncologyMaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationKaplan-Meier EstimateCohort Studies0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceChildAcute leukemiaUnivariate analysisHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsLeukemiaLeukemia Myeloid Acutesurgical procedures operative030220 oncology & carcinogenesisChild PreschoolLymphocyte TransfusionFemaleLeukocyte Reduction ProceduresAdultmedicine.medical_specialtyAdolescentGraft vs Leukemia EffectDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicineGeneticsmedicineHumansMolecular BiologyAgedRetrospective StudiesImmunosuppression TherapySalvage Therapybusiness.industryCell Biologymedicine.diseaseTransplantationbusiness030215 immunologyExperimental hematology
researchProduct

Local adaptation in populations of Mycobacterium tuberculosis endemic to the Indian Ocean Rim

2021

24 páginas, 3 figuras, 1 tabla. The sequence data generated by this study has been deposited on SRA (https://www.ncbi.nlm.nih.gov/sra) under the accession number PRJNA670836. Extended data is available here: https://github.com/fmenardo/MTBC_L1_L3. DOI: https://doi.org/10.5281/zenodo.4609804 (Menardo, 2021).

0301 basic medicineMycobacterium tuberculosis / patogenicidadeTuberculosisGenotypevirusesLineage (evolution)030106 microbiologyLocus (genetics)adaptationBiologyGenomeGeneral Biochemistry Genetics and Molecular BiologyMycobacterium tuberculosis03 medical and health sciencesAdapta??oGenoma BacterianomedicineHumansOceano ?ndico / epidemiologiaGeneral Pharmacology Toxicology and PharmaceuticsAdaptationIndian OceanLocal adaptationGenetic diversityGeneral Immunology and Microbiologyvirus diseasesTuberculose / patologiaGeneral MedicineArticlesMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionbiology.organism_classificationmedicine.diseasedigestive system diseases3. Good health030104 developmental biologyMycobacterium tuberculosis complexEvolutionary biologycoevolutionLinhagemCoevolutionResearch ArticleF1000Research
researchProduct

Studying hypertension in ocular fundus images using Hausdorff dispersion ordering.

2010

Retinal arterial and vein diameters are altered in individuals at risk of cardiovascular events mainly due to high blood pressure. The measurement of retinal vessel diameters has been proved to reflect individuals' vascular health. Dispersion of such measures which are obtained by means of ocular fundus images is a major factor not usually considered in clinical research. In this paper, a method to evaluate if different levels of clinically relevant covariables induce greater dispersion in retinal arterial and vein diameters is proposed. A multivariate dispersion ordering, the Hausdorff dispersion order, is used to compare the level of dispersion in such diameters for different groups of pa…

medicine.medical_specialtyFundus OculiGeneral Biochemistry Genetics and Molecular BiologyRetinaVascular healthchemistry.chemical_compoundOphthalmologymedicineImage Processing Computer-AssistedHumansStatistical dispersionVeinGeneral Environmental SciencePharmacologyGeneral Immunology and Microbiologybusiness.industryApplied MathematicsGeneral NeuroscienceRetinal VesselsRetinalGeneral MedicineRetinal vesselBlood pressuremedicine.anatomical_structurechemistryHomogeneousModeling and SimulationHypertensionbusinessMathematical medicine and biology : a journal of the IMA
researchProduct

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

2014

BRAF-V600E expression is identified in hematopoietic progenitor and precursor myeloid dendritic cells in patients with high-risk LCH, and enforced expression of BRAF-V600E in CD11c+ cells recapitulates a high-risk LCH-like phenotype in mice.

MalePathologyendocrine system diseasesCellular differentiationCD34Antigens CD34Mice0302 clinical medicineLangerhans cell histiocytosisBone MarrowRisk FactorsImmunology and Allergyskin and connective tissue diseasesChild0303 health sciencesCell Differentiation3. Good healthHistiocytosismedicine.anatomical_structurePhenotypeTreatment Outcome030220 oncology & carcinogenesisChild PreschoolAntigens Surface2723 Immunology and AllergyFemaleProto-Oncogene Proteins B-rafmedicine.medical_specialtyImmunologyCD11c610 Medicine & healthBiologyArticle03 medical and health sciencesGermline mutationmedicineAnimalsHumansCell LineageGenetic Predisposition to DiseaseLectins C-TypeProgenitor cellneoplasms030304 developmental biology2403 ImmunologyHistocompatibility Antigens Class II302InfantCorrectionDendritic Cellsmedicine.diseaseHematopoietic Stem Cellsdigestive system diseasesCD11c Antigenenzymes and coenzymes (carbohydrates)Histiocytosis Langerhans-CellMannose-Binding Lectins10032 Clinic for Oncology and HematologyMutationBone marrowThe Journal of experimental medicine
researchProduct

The nucleosome-remodeling ATPase ISWI is regulated by poly-ADP-ribosylation.

2008

ATP-dependent nucleosome-remodeling enzymes and covalent modifiers of chromatin set the functional state of chromatin. However, how these enzymatic activities are coordinated in the nucleus is largely unknown. We found that the evolutionary conserved nucleosome-remodeling ATPase ISWI and the poly-ADP-ribose polymerase PARP genetically interact. We present evidence showing that ISWI is target of poly-ADP-ribosylation. Poly-ADP-ribosylation counteracts ISWI function in vitro and in vivo. Our work suggests that ISWI is a physiological target of PARP and that poly-ADP-ribosylation can be a new, important post-translational modification regulating the activity of ATP-dependent nucleosome remodel…

Poly Adenosine Diphosphate RiboseImmunoprecipitationQH301-705.5Poly ADP ribose polymeraseATPaseBlotting WesternBiochemistryChromosomesGeneral Biochemistry Genetics and Molecular BiologySettore BIO/10 - BiochimicaAnimalsDrosophila ProteinsImmunoprecipitationNucleosomeBiology (General)Transcription factorIn Situ Hybridization FluorescencePolymeraseAdenosine TriphosphatasesGeneral Immunology and MicrobiologybiologyGeneral NeuroscienceGenetics and GenomicsPARP ISWI Poly(ADP)ribosylation Chromatin remodellingCell BiologyChromatinISWI PARPNucleosomesChromatinSettore BIO/18 - GeneticaDrosophila melanogasterBiochemistrybiology.proteinPoly(ADP-ribose) PolymerasesGeneral Agricultural and Biological SciencesFunction (biology)Transcription FactorsResearch ArticlePLoS Biology
researchProduct

Effects of a Rehabilitation Program on Perceived Environmental Barriers in Older Patients Recovering from Hip Fracture: A Randomized Controlled Trial

2013

Objectives. To study effects of a one-year multicomponent intervention on perceived environmental barriers in hip fracture patients.Design. Randomized controlled trial of a 12-month home-based rehabilitation aiming to improve mobility and function (ISRCTN53680197); secondary analyses.Subjects. Community-dwelling hip fracture patients on average 70 days after trauma (n=81).Methods. Assessments at baseline, 3, 6, and 12 months later included perceived entrance-related barriers (e.g., indoor/outdoor stairs, lighting, floor surfaces, and storage for mobility devices) and perceived barriers in the outdoor environment (poor street condition, hilly terrain, long-distances, and lack of resting plac…

medicine.medical_specialtyMultivariate analysisTime FactorsympäristöArticle Subjectmedicine.medical_treatmentPsychological interventionlcsh:MedicineEnvironmentGeneral Biochemistry Genetics and Molecular Biologylaw.inventionfemoral fracturePhysical medicine and rehabilitationStairsOlder patientsRandomized controlled triallawmedicineta319HumansAgedAged 80 and overHip fractureRehabilitationGeneral Immunology and Microbiologybusiness.industryHip Fractureskotikuntoutuslcsh:RagingCase-control studyGeneral Medicinemedicine.diseaseikääntyminensaavutettavuusCase-Control StudiesMultivariate AnalysisPhysical therapyClinical Studykuntoutuslonkkamurtumaesteettömyys ja saavutettavuusbusinessBioMed Research International
researchProduct

AN IL-6/IL-6 SOLUBLE RECEPTOR (IL-6R) HYBRID PROTEIN (H-IL-6) INDUCES EPO-INDEPENDENT ERYTHROID DIFFERENTIATION IN HUMAN CD34+CELLS

2000

H-IL-6 is a hybrid protein constructed to contain IL-6 and its soluble receptor linked by a flexible peptide chain. Here we show that H-IL-6 strongly enhances proliferation of human CD34(+)cells in serum-free liquid culture, and that the majority of the cells generated belong to the erythroid lineage, being positive for the marker Glycophorin A. Conversely, H-IL-6 does not increase the number of myeloid, CD13-positive cells. Comparable effects are observed on progenitors from cord blood and adult peripheral blood. Therefore, H-IL-6 triggers an erythroid-inducing signal in haematopoietic progenitor cells, independently from erythropoietin (EPO).

ErythrocytesTime FactorsMyeloidCellular differentiationInterleukin 6Antigens CD34BiochemistryCulture Media Serum-FreeSerum-Freehemic and lymphatic diseasesReceptorsLeukocytesImmunology and AllergyErythropoiesisGlycophorinsStem Cell FactorbiologyChemistryCord bloodCell DifferentiationHematologyFetal BloodFlow CytometryEndothelial stem cellHaematopoiesismedicine.anatomical_structureGlycophorinCD34+medicine.drugRecombinant Fusion ProteinsMononuclearImmunologyCD13 AntigensmedicineHumansGlycophorinAntigensProgenitor cellErythropoietinMolecular BiologyInterleukin 3Interleukin-6CD34+; Cord blood; Erythropoiesis; Interleukin 6; Stem cell factor; Antigens CD34; CD13 Antigens; Cell Differentiation; Culture Media Serum-Free; Erythrocytes; Erythropoietin; Fetal Blood; Flow Cytometry; Glycophorin; Hematopoietic Stem Cells; Humans; Interleukin-6; Leukocytes Mononuclear; Peptides; Receptors Interleukin-6; Recombinant Fusion Proteins; Stem Cell Factor; Time Factors; Immunology and Allergy; Immunology; Biochemistry; Hematology; Molecular BiologyHematopoietic Stem CellsReceptors Interleukin-6Molecular biologyCulture MediaErythropoietinLeukocytes Mononuclearbiology.proteinCD34PeptidesCytokine
researchProduct

Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data

2018

Background The X-ACT study aims to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1-antihistamines. Methods In X-ACT, a phase III, double-blind, placebo-controlled study, CSU patients (18–75 years) with ≥4 angioedema episodes during the 6 months before inclusion were randomized (1:1) to receive omalizumab 300 mg or placebo every 4 weeks for 28 weeks. Angioedema-related QoL, skin-related QoL impairment, and psychological well-being were assessed. Results Ninety-one patients were randomized and 68 (omalizumab, n=35; placebo, n=33) completed the 28-week treatment period. At baselin…

AdultMalechronic spontaneous urticariamedicine.medical_specialtyAdolescentUrticariaImmunologyOmalizumab600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::616 KrankheitenPlaceboYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDouble-Blind MethodRefractoryQuality of lifeInternal medicine616Anti-Allergic AgentsmedicineHumansH1-antihistamine-refractoryImmunology and AllergyDepression (differential diagnoses)AgedAngioedemaAdult patientsbusiness.industryangioedemaDermatology Life Quality IndexMiddle AgedSurgeryquality of life030228 respiratory systemExperimental Allergy and ImmunologyomalizumabOriginal ArticleFemaleORIGINAL ARTICLESH1‐antihistamine‐refractorymedicine.symptombusinessmedicine.drugAllergy
researchProduct

Independence between developmental stability and canalization in the skull of the house mouse.

2000

The relationship between the two components of developmental homeostasis, that is canalization and developmental stability (DS), is currently debated. To appraise this relationship, the levels and morphological patterns of interindividual variation and fluctuating asymmetry were assessed using a geometric morphometric approach applied to the skulls of laboratory samples of the house mouse. These three samples correspond to two random-bred strains of the two European subspecies of the house mouse and their F1 hybrids. The inter- and intraindividual variation levels were found to be smaller in the hybrid group compared to the parental ones, suggesting a common heterotic effect on skull canali…

MorphogenesisZoologyBiologySubspeciesGeneral Biochemistry Genetics and Molecular BiologyFluctuating asymmetryHouse mouseLoss of heterozygosityMiceGenetic variationmedicineMorphogenesisAnimalsHomeostasisGeneral Environmental ScienceHybridGeneral Immunology and MicrobiologySkullGenetic VariationGeneral Medicinebiology.organism_classificationSkullmedicine.anatomical_structureEvolutionary biologyBody ConstitutionGeneral Agricultural and Biological SciencesMonte Carlo MethodResearch ArticleProceedings. Biological sciences
researchProduct

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leu…

2015

Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (3 g/m(2)/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m(2) intravenously on days 2-3) in 93 patients aged 18-60 years refractory to one cycle of induction therapy. Primary end point of the study was response to therapy; secondary end points included evaluation of toxicities, in particular, rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell tr…

AdultMalemedicine.medical_specialtyGemtuzumab ozogamicinmedicine.medical_treatmentSalvage therapyTretinoinComorbidityKaplan-Meier EstimateAntibodies Monoclonal HumanizedGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansSalvage TherapyMitoxantroneChemotherapybusiness.industryRemission InductionCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyArticlesMiddle Agedmedicine.diseaseGemtuzumab3. Good healthSurgeryTransplantationConsolidation ChemotherapyLeukemiaLeukemia Myeloid AcuteAminoglycosidesTreatment Outcome030220 oncology & carcinogenesisCytarabineFemaleMitoxantronebusiness030215 immunologymedicine.drugHaematologica
researchProduct